

# Nathalie LeVasseur

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3631742/publications.pdf>

Version: 2024-02-01

21  
papers

213  
citations

1307594

7  
h-index

1058476

14  
g-index

22  
all docs

22  
docs citations

22  
times ranked

301  
citing authors

#	ARTICLE	IF	CITATIONS
1	Bone-targeted therapy use in patients with bone metastases from lung cancer: A systematic review of randomized controlled trials. <i>Cancer Treatment Reviews</i> , 2016, 50, 183-193.	7.7	39
2	Optimal vascular access strategies for patients receiving chemotherapy for early-stage breast cancer: a systematic review. <i>Breast Cancer Research and Treatment</i> , 2018, 171, 607-620.	2.5	37
3	Impact of pathologic complete response on survival after neoadjuvant chemotherapy in early-stage breast cancer: a population-based analysis. <i>Journal of Cancer Research and Clinical Oncology</i> , 2020, 146, 529-536.	2.5	37
4	Optimizing Vascular Access for Patients Receiving Intravenous Systemic Therapy for Early-Stage Breast Cancer—A Survey of Oncology Nurses and Physicians. <i>Current Oncology</i> , 2018, 25, 298-304.	2.2	24
5	Perceptions of Vascular Access for Intravenous Systemic Therapy and Risk Factors for Lymphedema in Early-Stage Breast Cancer—A Patient Survey. <i>Current Oncology</i> , 2018, 25, 305-310.	2.2	18
6	Efficacy of Neoadjuvant Endocrine Therapy Versus Neoadjuvant Chemotherapy in ER-positive Breast Cancer: Results From a Prospective Institutional Database. <i>Clinical Breast Cancer</i> , 2019, 19, e683-e689.	2.4	12
7	Optimising weight-loss interventions in cancer patients—A systematic review and network meta-analysis. <i>PLoS ONE</i> , 2021, 16, e0245794.	2.5	11
8	Impact of the 21-Gene Recurrence Score Assay on the Treatment of Estrogen Receptor-Positive, HER2-Negative, Breast Cancer Patients With 1-3 Positive Nodes: A Prospective Clinical Utility Study. <i>Clinical Breast Cancer</i> , 2022, 22, e74-e79.	2.4	8
9	Effects of High Anxiety Scores on Surgical and Overall Treatment Plan in Patients with Breast Cancer Treated with Neoadjuvant Therapy. <i>Oncologist</i> , 2020, 25, 212-217.	3.7	7
10	Neoadjuvant endocrine therapy and window of opportunity trials: new standards in the treatment of breast cancer?. <i>Minerva Chirurgica</i> , 2015, 70, 181-93.	0.8	6
11	Clinical utility of MRI in the neoadjuvant management of early-stage breast cancer. <i>Breast Cancer Research and Treatment</i> , 0, , .	2.5	4
12	Examining social media peer support and improving psychosocial outcomes for young women with breast cancer.. <i>Journal of Clinical Oncology</i> , 2021, 39, 162-162.	1.6	3
13	Cancer screening and prevention in BRCA mutation carriers: a missed opportunity?. <i>British Journal of Cancer</i> , 2019, 121, 1-2.	6.4	2
14	Sequential versus concurrent chemotherapy for adjuvant breast cancer: does dose intensity matter?. <i>British Journal of Cancer</i> , 2017, 117, 157-158.	6.4	1
15	Unnecessary Variation in Practice: How to Improve Cancer Care through Pragmatic Trials. <i>Current Oncology</i> , 2018, 25, 263-264.	2.2	1
16	Impact of sequence order of anthracyclines and taxanes in neoadjuvant chemotherapy on pathologic complete response rate in HER2-negative breast cancer patients. <i>Breast Cancer Research and Treatment</i> , 2021, 187, 167-176.	2.5	1
17	Comparing outcomes of neoadjuvant endocrine therapy versus chemotherapy in ER-positive breast cancer: Results from a prospective institutional database.. <i>Journal of Clinical Oncology</i> , 2017, 35, 581-581.	1.6	1
18	Whole genome sequencing in metastatic breast cancer: Lessons learned from the BC Cancer personalized oncogenomics program.. <i>Journal of Clinical Oncology</i> , 2018, 36, 12065-12065.	1.6	1

#	ARTICLE	IF	CITATIONS
19	Can We Hang Our Hats on One Percent?. <i>Oncologist</i> , 2018, 23, 642-644.	3.7	0
20	Weight control strategies in breast cancer patients: A systematic review.. <i>Journal of Clinical Oncology</i> , 2016, 34, 179-179.	1.6	0
21	Optimal weight control strategies in cancer patients: A systematic review.. <i>Journal of Clinical Oncology</i> , 2016, 34, 10109-10109.	1.6	0